Before I start, don’t forget my deal of the day! Today back by popular demand I have the TradeKing deal. Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, just a simple click on a link!!!!
Get $50 when you open a TradeKing account today. » Read more: Ugh, More Politics for Stem Cell Companies
Geron Corporation (GERN): The Story of the Day
Geron received really positive news this morning. The company said that the FDA has notified the company that the clinical trial hold that was placed on their Stem Cell Phase I clinical trials is now allowed to proceed. » Read more: Geron Corporation (GERN): The Story of the Day
Daily Pharma Watch
Hemispherx (HEB):
Hemispherx Biopharma said this morning that one of their drugs was approved for use in by the Indian Drugs Controller for Phase II clinical trials. The trial will test Alferonn on patients suffering from influenza. However, investors are more focused on what HemispherX is going to do to move forward the advancement of Ampligen, their lead product. Last year, the drug was rejected by the FDA and the company was issued a complete response letter for use in Chronic Fatigue Syndrome (CFS) patients. In the letter the FDA requested that the company run another clinical trial on the patients with more thorough and rigorous safety and efficacy endpoints. » Read more: Daily Pharma Watch
Geron (GERN):
Geron said this morning that they have seen positive data in an animal model of their small molecule telomerase activator TAT153 in idiopathic pulmonary fibrosis (IPF). The data looked positive and showed that TAT153 reduced inflammation, preserved lung function and slowed progression of the disease in the model. However, the drug is several years out in development, but there are currently not many options out there for patients of IPF and a new treatment hasn’t been approved for over 50 years. » Read more: Daily Pharma Watch
Alright, today I am going to give an overview of Geron’s lead Stem Cell Product: Human Embryonic Stem Cell Oligodendrocytes. In this analysis I’ll focus on how the Stem Cells work, the cited studies, and what was behind the hold up of their lead clinical trial in Spinal Cord injury patients. » Read more: Geron’s Stem Cell Therapies: The Low Down
Geron’s GRNVAC1: A Brief Analysis
Alright pharma investors, today I am going to call brief attention to one of Geron’s other cancer vaccines. The vaccine is called GRNVAC1 and there was a recent release of interim data at last years ASH meeting. » Read more: Geron’s GRNVAC1
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter